Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents

Abstract

Oritavancin exhibited in vitro activity against 169 strains of vancomycin-susceptible, methicillin-resistant Staphylococcus aureus (MRSA) with MICs ranging from 0.03 to 1μg/ml and against vancomycin-intermediate MRSA (VISA; n=29), heterogeneous vancomycin-intermediate MRSA (hVISA; n=5), and vancomycin-resistant MRSA (n=5) strains, with MICs ranging from 0.12 to 4μg/ml. For 10 MRSA isolates comprising 5 VISA and 5 hVISA strains, synergy between oritavancin and gentamicin, linezolid, or rifampin was observed against most of the strains tested using a time-kill method. Copyright